A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil

Sildenafil is a phosphodiesterase-type-5 inhibitor indicated for the treatment of erectile dysfunction in men. We report a case of NAION identified from a cohort of 8,893 patients (from a Prescription-Event Monitoring study) prescribed sildenafil by their primary care physician in England between Ap...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of clinical pharmacology and therapeutics Vol. 40; no. 9; p. 422
Main Authors Boshier, A, Pambakian, N, Shakir, S A W
Format Journal Article
LanguageEnglish
Published Germany 01.09.2002
Subjects
Humans
Male
Middle Aged
Optic Neuropathy, Ischemic - chemically induced
Optic Neuropathy, Ischemic - physiopathology
Piperazines - adverse effects
Product Surveillance, Postmarketing
Purines
Sildenafil Citrate
Sulfones
Online AccessGet more information

Cover

More Information
Summary:Sildenafil is a phosphodiesterase-type-5 inhibitor indicated for the treatment of erectile dysfunction in men. We report a case of NAION identified from a cohort of 8,893 patients (from a Prescription-Event Monitoring study) prescribed sildenafil by their primary care physician in England between April and June 1999. This 61-year-old patient had risk factors for NAION independent of drug therapy. It was not possible to be confident about a causal association between sildenafil and NAION, though the possibility could not be ruled out. Epidemiological data suggest that one case of NAION might be expected in a cohort of 8,893 subjects. Thus it remains important for clinicians to consider the range of risk factors for NAION; while equally, the processes of pharmacovigilance need to continue as for any recently launched drug preparation.
ISSN:0946-1965
DOI:10.5414/CPP40422